The Narodowy Fundusz Zdrowia is the National Health Fund of Poland. It was established by Act of the Sejm of 27 August 2004 on a proposal of Mariusz Lipinski, then the minister of health that there should be just one centralized government institution..
Abstract Background Cardiovascular diseases remain the leading cause of premature mortality in Europe, yet contemporary population-level data on modifiable risk factors in adults eligible for primary prevention are limited. Large-scale screening programmes enable detailed assessment of age- and sex-specific patterns relevant to preventive strategies. Purpose To evaluate the prevalence and age- and sex-specific patterns of major modifiable cardiovascular risk factors in a large cohort of adults participating in a preventive screening programme. Methods We analysed adults aged 35–65 years screened between 2022 and 2024. Standardised assessments included blood pressure, fasting glucose, total cholesterol, body-mass index, smoking, and physical activity. Individuals with cardiovascular disease, diabetes, chronic kidney disease, or familial hypercholesterolaemia were excluded. Analyses were stratified by age, sex, and year. Linear and polynomial regression models assessed age-related and temporal trends (p<0.05). Results Among 1 187 168 adults, women constituted 59–63% (p<0.001). Overweight affected 33.3–34.0% of women and 46.9–47.0% of men (p<0.001), while obesity reached 21.3–22.2% and 29.8–30.3% (p<0.001). In women, both increased steadily with age (p<0.05), whereas in men obesity peaked in midlife (p<0.05). Hypertension occurred in 21.0–23.0%, with higher prevalence in men (29.8–31.5%) than women (15.8–17.1%; p<0.001) and increased with age in both sexes (p<0.05). Elevated cholesterol was most frequent (63.5–66.9%) and exceeded 75% in older women, with sex-specific age trajectories (p<0.05); levels increased in men across study years (p=0.047). Newly detected diabetes rose sharply with age, reaching 5.0% in men aged 60–65 years (p<0.001 across groups). Smoking remained common (19–20% of women; 28% of men; p<0.001), while low physical activity affected ~50% and showed opposite age patterns in women (declining) and men (increasing) (both p<0.05). Conclusion This large contemporary cohort demonstrated a high burden of modifiable cardiovascular risk factors, with consistent and clinically relevant sex- and age-specific disparities. Men showed substantially higher levels of hypertension, dyslipidaemia, excess body weight, smoking, and hyperglycaemia, while women exhibited a marked age-related rise in obesity and cholesterol. These findings underscore the need for targeted, sex- and age-adapted primary prevention strategies to improve cardiovascular risk control.
Objective:This ecological study describes population-level trends in obesity, sugar-sweetened beverage (SSB) consumption, per-capita sugar purchases and publicly funded healthcare use for obesity-related conditions in Poland around the introduction of a sugar tax in 2021. Methods:We analyzed nationally aggregated administrative and survey data from the National Health Fund (NHF), the e-Health Center, the Central Statistical Office (CSO) and the National Public Health Institute (NPHI). Annual time series (2014-2024, where available) on per-capita sugar purchases and healthcare use for obesity and major obesity-related comorbidities were evaluated using segmented time-series regression with a 2021 break-point and a COVID-19 (2020) indicator. Survey-based data on SSB and sweets consumption and on overweight and obesity (2018, 2022, 2025), plus cross-sectional BMI data for 2025, were summarized descriptively. Results:Per-capita sugar purchases decreased moderately between 2018 and 2024. Survey data indicated an initial reduction in SSB consumption after 2021, followed by partial rebound by 2025, and a shift towards more frequent sweets consumption, while overweight and obesity continued to rise. For obesity-related conditions, numbers of patients receiving disease-specific healthcare showed a COVID-19-related dip in 2020 and subsequent post-2021 increases, with bariatric surgery and pharmacological treatment of obesity also rising over the study period. Conclusion:In the first 4 years after sugar tax implementation, we observed modest declines in per-capita sugar purchases, transient reductions in SSB consumption and increasing sweets consumption, alongside continued growth in obesity and obesity-related healthcare use. Given the ecological design and short follow-up, these findings represent temporal associations rather than evidence of direct causal effects and underline the need to embed fiscal measures such as a sugar tax within broader, multi-level strategies for obesity prevention, health promotion and access to effective obesity treatment.
Background Evidence on mortality trends among people with diagnosed HIV (PHIV-D) in Central European region is limited. We aimed to compare the mortality rates between general and HIV positive population and investigate the trends during 2012–2024 in Poland. Methods In this database study on the in the public payer, National Health Fund, claims data linked with census registry we applied an algorithm to identify PHIV-D, relying on the number of HIV-related and other claims. We estimated per year: number of PHIV-D aged 18+, mortality rate and standardized mortality ratio (SMR) for general population comparison. Kaplan-Meyer estimator and Cox proportional hazard model reporting adjusted hazard ratios (HR) were used for overall survival among newly diagnosed. Results PHIV-D population increased from 8.1 thousands in 2012 to 18.6 thousands in 2024, with proportion of females decreasing from 25% to 19%. In 2012–2024 there were 16,040 new diagnoses and 2621 deaths among adults aged 18 and older. The total number of deaths recorded in 18–64 age group was 2,386 and the mortality in this group group decreased from 2.66% in 2012 to 1.47% in 2024, and SMR, with respect to general population of comparable age, decreased from 18.2 to 8.8 in females and from 6.6 to 3.4 in males. Survival increased significantly with year of diagnosis and was lower in case of AIDS at diagnosis (HR 4.21, 95% CI 3.79–4.69) and during COVID-19 pandemic (HR 1.22, 95% CI 0.99–1.50) vs before pandemic. Conclusion The PHIV-D, in particular women with HIV, are at much higher risk of death than the general population. This difference is relatively large as compared to studies in other countries, which could be partially explained by frequent late presentation.
Abstract Background Despite effective and innovative contemporary therapies, survivors of acute myocardial infarction (AMI) remain at high risk for recurrent events and death. In Poland, two distinct nationwide pathways address this risk: KOS-Zawał, a multidisciplinary programme combining early cardiac rehabilitation, lifestyle counselling, and systematic follow-up, which has already demonstrated substantial efficacy, and the drug program B.101, a pharmacotherapy-centred pathway providing intensive combination lipid-lowering therapy with PCSK9 modulators for MI patients. Robust head-to-head data comparing these two effective strategies are lacking. Purpose To assess whether participation in the B.101 drug program favourably affects endpoints in post-MI patients compared to those participating in the KOS-Zawał program and not included in the drug program. Methods Patients who participated in the KOS-Zawał program between 2021-2024 and experienced an AMI during their program care period (within 30 days) were included. Similarly, patients who began the B.101 program under the "very high cardiovascular risk" branch between 2021–2024 were selected. Those who appeared in both investigated groups simultaneously were excluded from the defined population. Both groups were matched using propensity score matching (PSM) that was conducted in a 4:1 ratio (KOS-Zawał:B.101). The groups were compared in terms of endpoints: all-cause mortality, and the composite of death or AMI occurrence. Results The final dataset included 1,760 patients (n=352 in the B.101 group and n=1,408 in the KOS-Zawał group), comprising 1,200 men (68.2%) and 560 women, with a mean age of 60.6 years. Diabetes was diagnosed in 28% of patients, obesity in 6.5%, chronic kidney disease in 5.7%, and stroke or TIA in 4%. Based on logistic regression analysis over a follow-up of 2 years, there were no statistically significant differences for all-cause mortality or the composite endpoint (KOS-Zawał vs. B.101 program; OR=1.83, p=0.287, and OR=1.28, p=0.506). Based on the Cox proportional hazards model with a longer follow-up of 4.4 years, the KOS-Zawał comprehensive program, compared to the treatment of patients with PCSK9 modulators in the B101 program, was associated with a significantly higher risk of death (HR=3.28; 95%CI: 1.52–7.07) (Figure 1A) and the composite of death or recurrent acute myocardial infarction (HR=1.70; 95%CI: 1.10–2.63) (Figure 1B). Conclusions The B101 drug program, where patients are treated with intensive combination LLT including statins, ezetimibe, and PCSK9 inhibitors or inclisiran, is associated with a significant 70% lower risk of all-cause mortality and a 41% lower risk of death or recurrent AMI compared to patients included in the coordinated comprehensive post-MI care program. These findings suggest that, for optimal healthcare outcomes, the B.101 drug program should be made available to all patients enrolled in KOS-Zawał.Figure